State Requirement Info
5 courses found
1
https://www.physicaltherapy.com/pt-ceus/course/pharmacology-for-the-endocrine-system-5432
GLP-1s and More: Pharmacology for Diabetes Mellitus and Other Endocrine Conditions
Diabetes mellitus, hypothyroidism, and osteoporosis are conditions often seen as a primary or secondary diagnosis in therapy practice. Thus, therapists across the healthcare continuum need to appreciate the indications, mechanism of action, side effects, and implications for therapists of the various medication classes to treat these endocrine disorders.
auditory, textual, visual
129
USD
Subscription
Unlimited COURSE Access for $129/year
OnlineOnly
PhysicalTherapy.com
www.physicaltherapy.com
GLP-1s and More: Pharmacology for Diabetes Mellitus and Other Endocrine Conditions
Diabetes mellitus, hypothyroidism, and osteoporosis are conditions often seen as a primary or secondary diagnosis in therapy practice. Thus, therapists across the healthcare continuum need to appreciate the indications, mechanism of action, side effects, and implications for therapists of the various medication classes to treat these endocrine disorders.
5432
Online
PT120M
GLP-1s and More: Pharmacology for Diabetes Mellitus and Other Endocrine Conditions
Presented by Melissa Bednarek, PT, DPT, PhD, CCS
Course: #5432Level: Intermediate2 Hours
AK/2.0; AL/2.0; AR/2.0; AZ/2.0; CA/2.0; CO/2.0; CT/2.0; DC/2.0; DE/2.0; FL/2.0; GA/2.0; HI/2.0; IA/2.0; IACET/0.2; ID/2.0; IL/2.0; IN/2.0; KS/2.0; KY/2.0; MA/2.0; MD/2.0; ME/2.0; MI/2.0; MO/2.0; MS/2.0; MT/2.0; NC/2.0; ND/2.0; NE/2.0; NH/2.0; NY/2.0; OK/2.0; OR/2.0; PA/2.0; RI/2.0; SC/2.0; SD/2.0; TX/2.0; UT/2.0; VA/2.0; VT/2.0; WA/2.0; WI/2.0; WY/2.0
Diabetes mellitus, hypothyroidism, and osteoporosis are conditions often seen as a primary or secondary diagnosis in therapy practice. Thus, therapists across the healthcare continuum need to appreciate the indications, mechanism of action, side effects, and implications for therapists of the various medication classes to treat these endocrine disorders.
2
https://www.physicaltherapy.com/pt-ceus/course/navigating-polypharmacy-and-multi-morbidity-5537
Navigating Polypharmacy and Multi-Morbidity: A PT's Guide to Exercise Optimization and Patient Management
Seventy-three percent of older adults have two chronic conditions, and 36% have four or more, leading to management with polypharmacy. One in 5 older adults uses 5 or more prescription medications and is taking a medication that adversely affects a co-existing condition. Polypharmacy bidirectionally impacts physical function and, therefore, physical activity. Adults who participate in aerobic and strengthening activity recommendations have a greatly reduced risk for all-cause mortality. Physical therapists who understand how the movement system interacts with multimorbidity and polypharmacy are uniquely qualified to guide complex patients through safe and effective exercise programs to improve physical function and reduce mortality. This session will use the ACSM exercise recommendation guidelines to consider each multimorbidity’s effect on the exercise prescription, balance polypharmacy considerations, and maximize patient safety and exercise dosing for meaningful results. Using exemplar cases, the learner will be challenged to recognize patterns of multimorbidity and pharmacotherapy, discuss the role of the physical therapist within the multidisciplinary team and in patient communication, and optimize patient outcomes. The Beers List of potentially inappropriate medications to be avoided in older adults will be incorporated, and a schema will be provided to integrate advanced clinical reasoning into the care of complex patients.
auditory, textual, visual
129
USD
Subscription
Unlimited COURSE Access for $129/year
OnlineOnly
PhysicalTherapy.com
www.physicaltherapy.com
Navigating Polypharmacy and Multi-Morbidity: A PT's Guide to Exercise Optimization and Patient Management
Seventy-three percent of older adults have two chronic conditions, and 36% have four or more, leading to management with polypharmacy. One in 5 older adults uses 5 or more prescription medications and is taking a medication that adversely affects a co-existing condition. Polypharmacy bidirectionally impacts physical function and, therefore, physical activity. Adults who participate in aerobic and strengthening activity recommendations have a greatly reduced risk for all-cause mortality. Physical therapists who understand how the movement system interacts with multimorbidity and polypharmacy are uniquely qualified to guide complex patients through safe and effective exercise programs to improve physical function and reduce mortality. This session will use the ACSM exercise recommendation guidelines to consider each multimorbidity’s effect on the exercise prescription, balance polypharmacy considerations, and maximize patient safety and exercise dosing for meaningful results. Using exemplar cases, the learner will be challenged to recognize patterns of multimorbidity and pharmacotherapy, discuss the role of the physical therapist within the multidisciplinary team and in patient communication, and optimize patient outcomes. The Beers List of potentially inappropriate medications to be avoided in older adults will be incorporated, and a schema will be provided to integrate advanced clinical reasoning into the care of complex patients.
5537
Online
PT120M
Navigating Polypharmacy and Multi-Morbidity: A PT's Guide to Exercise Optimization and Patient Management
Presented by Robin Schroeder, PT DPT, GCS, OCS, CSCS, CLT, A-CEEAA
Course: #5537Level: Advanced2 Hours
AK/2.0; AL/2.0; AR/2.0; AZ/2.0; CA/2.0; CO/2.0; CT/2.0; DC/2.0; DE/2.0; FL/2.0; GA/2.0; HI/2.0; IA/2.0; IACET/0.2; ID/2.0; IL/2.0; IN/2.0; KS/2.0; KY/2.0; MA/2.0; MD/2.0; ME/2.0; MI/2.0; MO/2.0; MS/2.0; MT/2.0; NC/2.0; ND/2.0; NE/2.0; NH/2.0; NM/2.0; NY/2.0; OK/2.0; OR/2.0; PA/2.0; RI/2.0; SC/2.0; SD/2.0; TX/2.0; UT/2.0; VA/2.0; VT/2.0; WA/2.0; WI/2.0; WY/2.0
Seventy-three percent of older adults have two chronic conditions, and 36% have four or more, leading to management with polypharmacy. One in 5 older adults uses 5 or more prescription medications and is taking a medication that adversely affects a co-existing condition. Polypharmacy bidirectionally impacts physical function and, therefore, physical activity. Adults who participate in aerobic and strengthening activity recommendations have a greatly reduced risk for all-cause mortality. Physical therapists who understand how the movement system interacts with multimorbidity and polypharmacy are uniquely qualified to guide complex patients through safe and effective exercise programs to improve physical function and reduce mortality. This session will use the ACSM exercise recommendation guidelines to consider each multimorbidity’s effect on the exercise prescription, balance polypharmacy considerations, and maximize patient safety and exercise dosing for meaningful results. Using exemplar cases, the learner will be challenged to recognize patterns of multimorbidity and pharmacotherapy, discuss the role of the physical therapist within the multidisciplinary team and in patient communication, and optimize patient outcomes. The Beers List of potentially inappropriate medications to be avoided in older adults will be incorporated, and a schema will be provided to integrate advanced clinical reasoning into the care of complex patients.
3
https://www.physicaltherapy.com/pt-ceus/course/cannabis-implications-for-physical-and-5308
Cannabis: Implications for Physical and Occupational Therapy
Cannabis can be confusing: the different names, routes of administration, physiological effects, and legal aspects. This course will address all of these topics with a focus on implications for physical and occupational therapy.
auditory, textual, visual
129
USD
Subscription
Unlimited COURSE Access for $129/year
OnlineOnly
PhysicalTherapy.com
www.physicaltherapy.com
Cannabis: Implications for Physical and Occupational Therapy
Cannabis can be confusing: the different names, routes of administration, physiological effects, and legal aspects. This course will address all of these topics with a focus on implications for physical and occupational therapy.
5308
Online
PT120M
Cannabis: Implications for Physical and Occupational Therapy
Presented by Melissa Bednarek, PT, DPT, PhD, CCS
Course: #5308Level: Introductory2 Hours
AK/2.0; AL/2.0; AR/2.0; AZ/2.0; CA/2.0; CO/2.0; CT/2.0; DC/2.0; DE/2.0; FL/2.0; GA/2.0; HI/2.0; IA/2.0; IACET/0.2; ID/2.0; IL/2.0; IN/2.0; KS/2.0; KY/2.0; MA/2.0; MD/2.0; ME/2.0; MI/2.0; MO/2.0; MS/2.0; MT/2.0; NC/2.0; ND/2.0; NE/2.0; NH/2.0; NY/2.0; OK/2.0; OR/2.0; PA/2.0; RI/2.0; SC/2.0; SD/2.0; TX/2.0; UT/2.0; VA/2.0; VT/2.0; WA/2.0; WI/2.0; WY/2.0
Cannabis can be confusing: the different names, routes of administration, physiological effects, and legal aspects. This course will address all of these topics with a focus on implications for physical and occupational therapy.
4
https://www.physicaltherapy.com/pt-ceus/course/pharmacology-for-heart-failure-and-5175
Pharmacology for Heart Failure and COPD: Implications for Physical Therapy
Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are two chronic conditions for which medications and physical therapy are important parts of treatment. Thus, therapists across the healthcare continuum need to appreciate the indications, mechanism of action, side effects, and implications for physical therapy for the various medication classes for HF and COPD.
auditory, textual, visual
129
USD
Subscription
Unlimited COURSE Access for $129/year
OnlineOnly
PhysicalTherapy.com
www.physicaltherapy.com
Pharmacology for Heart Failure and COPD: Implications for Physical Therapy
Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are two chronic conditions for which medications and physical therapy are important parts of treatment. Thus, therapists across the healthcare continuum need to appreciate the indications, mechanism of action, side effects, and implications for physical therapy for the various medication classes for HF and COPD.
5175
Online
PT120M
Pharmacology for Heart Failure and COPD: Implications for Physical Therapy
Presented by Melissa Bednarek, PT, DPT, PhD, CCS
Course: #5175Level: Intermediate2 Hours
AK/2.0; AL/2.0; AR/2.0; AZ/2.0; CA/2.0; CO/2.0; CT/2.0; DC/2.0; DE/2.0; FL/2.0; GA/2.0; HI/2.0; IA/2.0; IACET/0.2; ID/2.0; IL/2.0; IN/2.0; KS/2.0; KY/2.0; MA/2.0; MD/2.0; ME/2.0; MI/2.0; MO/2.0; MS/2.0; MT/2.0; NC/2.0; ND/2.0; NE/2.0; NH/2.0; NY/2.0; OK/2.0; OR/2.0; PA/2.0; RI/2.0; SC/2.0; SD/2.0; TX/2.0; UT/2.0; VA/2.0; VT/2.0; WA/2.0; WI/2.0; WY/2.0
Heart failure (HF) and chronic obstructive pulmonary disease (COPD) are two chronic conditions for which medications and physical therapy are important parts of treatment. Thus, therapists across the healthcare continuum need to appreciate the indications, mechanism of action, side effects, and implications for physical therapy for the various medication classes for HF and COPD.
5
https://www.physicaltherapy.com/pt-ceus/course/glp-1-weight-loss-medications-4952
GLP-1 Weight Loss Medications: What Healthcare Providers Should Know!
The GLP-1 medications have become a popular treatment for individuals with type II diabetes or obesity. Healthcare providers must understand these medications, including the benefits, adverse effects, and contraindications. For some individuals, these medications can have consequences such as loss of lean mass loss, which can affect their function, health, and longevity. This presentation will provide an evidence-based update on this topic.
auditory, textual, visual
129
USD
Subscription
Unlimited COURSE Access for $129/year
OnlineOnly
PhysicalTherapy.com
www.physicaltherapy.com
GLP-1 Weight Loss Medications: What Healthcare Providers Should Know!
The GLP-1 medications have become a popular treatment for individuals with type II diabetes or obesity. Healthcare providers must understand these medications, including the benefits, adverse effects, and contraindications. For some individuals, these medications can have consequences such as loss of lean mass loss, which can affect their function, health, and longevity. This presentation will provide an evidence-based update on this topic.
4952
Online
PT120M
GLP-1 Weight Loss Medications: What Healthcare Providers Should Know!
Presented by Scott Cheatham, PhD, DPT, OCS, ATC, CSCS
Course: #4952Level: Advanced2 Hours
AK/2.0; AL/2.0; AR/2.0; AZ/2.0; BOC/2.0; CA/2.0; CO/2.0; CT/2.0; DC/2.0; DE/2.0; FL/2.0; GA/2.0; HI/2.0; IA/2.0; IACET/0.2; ID/2.0; IL/2.0; IN/2.0; KS/2.0; KY/2.0; LA/2.0; MA/2.0; MD/2.0; ME/2.0; MI/2.0; MO/2.0; MS/2.0; MT/2.0; NC/2.0; ND/2.0; NE/2.0; NH/2.0; NJ/2.0; NY/2.0; OK/2.0; OR/2.0; PA/2.0; RI/2.0; SC/2.0; SD/2.0; TX/2.0; UT/2.0; VA/2.0; VT/2.0; WA/2.0; WI/2.0; WY/2.0
The GLP-1 medications have become a popular treatment for individuals with type II diabetes or obesity. Healthcare providers must understand these medications, including the benefits, adverse effects, and contraindications. For some individuals, these medications can have consequences such as loss of lean mass loss, which can affect their function, health, and longevity. This presentation will provide an evidence-based update on this topic.